Steroid hormone production within the gonads and adrenals requires a continuous supply of cholesterol derived from de novo synthesis within the gland and from uptake of circulating plasma lipoproteins. Steroid hormone secretion was prospectively studied over 24 months in 64 hypercholesterolemic subjects (group I, aged 52 + 1 years [mean f SEMI, 61% male) participating in a randomized double-blind clinical trial of pravastatin (20 to 60 mg daily), a new 3-hydroxy-3-methylglutaryl coenryme A (HMG-CoA) reductase inhibitor, compared with patients taking cholestyramine or other lipid-lowering drugs (group II). Attempts were made in both groups to maintain serum low-density lipoprotein cholesterol (LDL-C) levels between the 25th and 50th percentile for age and gender. At 24 months, serum LDL-C level decreased by 42% + 3% in group I and 44% + 1% in group II (P c .OOl Y baseline, NS between groups). Basal secretion of cortisol, aldosterone, and dehydroepiandrostenedione sulfate (DHEA-S) was maintained throughout the study. However, the serum DHEA-S secretory response to Cortrosyn (Organon, West Orange, NJ) diminished in both treatment groups at 6 and 12 months (P < .05). In men, basal serum testosterone levels and the testosterone response to human chorionic gonadotropin (HCG) did not change. There was some diminution of sperm motility noted in both treatment groups at 6 and 12 months in the subset of men undergoing semen analysis (n = 14, P < .05). In conclusion, pravastatin had no significant effect on steroid metabolism. Changes noted in DHEA-S were not specific for pravastatin, suggesting that this impairment is related to lipid-lowering effects. c OMPLIANCE WITH the National Cholesterol Education Program Adult Treatment Guidelines' will permit large segments of the population to be treated for hypercholesterolemia over extended periods of time. The 3-hydroxy-3-methylglutaryl wenzyme A (HMG-CoA) reductase inhibitors are a new class of lipid-lowering agents that offer an effective and relatively safe intervention for the treatment of hypercholesterolemia.
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OMPLIANCE WITH the National Cholesterol Education Program Adult Treatment Guidelines' will permit large segments of the population to be treated for hypercholesterolemia over extended periods of time. The 3-hydroxy-3-methylglutaryl wenzyme A (HMG-CoA) reductase inhibitors are a new class of lipid-lowering agents that offer an effective and relatively safe intervention for the treatment of hypercholesterolemia.
An example of this class of drugs is lovastatin, which is found to produce 30% to 40% reductions in low-density lipoprotein cholesterol (LDL-C) levels.2-4 Pravastatin, another drug of this type with comparable lipid-lowering efficacy,5 is structurally similar, but its tissue specificity may vary.6,7 Few side effects have been reported with either lovastatin or pravastatin.
phosphate, a lipid-carrier molecule required for glycosylation of gonadotropins8
The possibility that inhibition of cholesterol synthesis may interfere with adrenal cortical and gonadal function is a concern for patients treated with these drugs. Lipidlowering agents may impair steroid hormone synthesis directly by decreasing the availability of circulating cholesterol for endocrine gland uptake (common to all hypolipidemit drugs) or diminishing in situ cholesterol synthesis (specific for HMG-CoA reductase inhibitors), or indirectly in the case of the gonads by altering levels of dolichol In cultured human fetal adrenal cortical cells, the majority of cholesterol was obtained via the LDL receptor pathway.g Subjects with heterozygous familial hypercholesterolemia have normal basal cortisol concentrations but attenuated cortisol responses to corticotropin administration.'O In the basal state, enhanced in situ cholesterol biosynthesis may compensate for defective uptake of LDL.'] Studies in small groups of genetically mixed hypercholesterolemic patients treated with lovastatin demonstrated variable effects on adrenal steroid hormone secretion.12-I4 Peak cortisol secretion was blunted after corticotropin administration in 24 patients treated for 8 weeks with simvastatin.14 Plasma aldosterone levels were within normal limits, but reduced after 9 months of simvastatin.15
Although in vitro basal and human chorionic gonadotropin (HCG)-stimulated testosterone production in rat Leydig cells was impaired with short-term lovastatin administration,15 serum testosterone levels were maintained in a clinical trial using lovastatin. I6 Degeneration of seminiferous epithelium in the testes has been observed in dogs receiving lovastatin 20 mgikg per day." Hyperlipidemic men maintained their serum levels of gonadotropins and semen analyses after 4 months of treatment with either neomycin or lovastatin.8 Recently in a study of porcine ovarian theta cells, lovastatin was noted to have an additional inhibitory action at the level of the 17-hydroxylase:C-17,20-lyase complex, resulting in decreased androstenedione production. I7 The present study was undertaken to determine the effects of long-term use of pravastatin, a new HMG-CoA reductase inhibitor, on adrenal and gonadal function in men and women. ments and publicized screenings to measure serum cholesterol. Subjects qualified for randomization into active treatment if they had three consecutive fasting serum LDL-C levels greater than both 160 mg/dL and the 75th percentile for age and sexI after at least 6 weeks of dietary compliance.
Serum triglyceride levels were lower than 250 mg/dL in all subjects. Patients were excluded if they had evidence of endocrine, renal, or hepatic disease, diabetes mrllitus (fasting blood glucose > 140 mg/dL), or unstable cardiac disease.
Pravastatin was used in a double-blind placebo-controlled clinical trial at four centers within the United States (Fig 1) . All subjects received a Step 1 American Heart Association lipidlowering diet"' for at least 6 weeks before randomization.
The diet was maintained throughout the study,'" and patients had regular follow-up visits with a dietitian to evaluate and reinforce dietary compliance.
A 4-week placebo lead-in period was included before randomization during the diet phase. Patients were randomized to receive either pravastatin (group I) or other hypocholesterolemic drugs (group II: predominantly cholestyramine). During the first 6 mctnt7s of the study. group I patients received pravastatin 40 mg daily plus placebo cholestyramine powder; group II patients recensed cholestyramine 16 g daily plus placebo tablets. Ten subjezts were taking only a placebo tablet for the first 4 months. These, patients were then rerandomized to an active treatment groul After 6 months, lipid-lowering medications could be adjusted in both groups to maintain serum LDL levels between the 25th and 50th percentile for age and sex. i8 In group I, the placebo powder wax discontinued at 6 months and pravastatin could be increased up to 80 mg daily; after 1 year, cholestyramine could be added to the tr:atment regimen for group I subjects. In group II. the placebo tablet for pravastatin was continued throughout the study period; five patients in Group II were allowed to start niacin or probucol treatment.
Thus, throughout the study, subjects were treated with II (cholestyramine up to 16 g daily) for 6 months. In group I, after 6 months pravastatin dosage could be increased to 80 mg daily and after 12 months cholestyramine could be added to maintain serum LDL-C levels between the 25th and 50th percentilel* for gender-and age-matched controls. In group II, chofestyramine dosage could be increased to 32 g daily after 6 months to maintain serum LDL-C levels at levels comparable to those in group I. Ten subjects were taking only a placebo tablet for the first 4 months and were then rerandomized to an active treatment group. Five patients in group II were allowed to start niacin or probucol treatment. Endocrine testing was performed 0,6,12,18, and 24 months after randomization.
varying doses I I pravastatin or cholestyramine depending on their serum lipid co,:entrations.
The study was approved by The Johns Hopkins Medic, Institutions Review Board: all patients gave informed consent.
Endocrine Testing
Hormone studies were performed at baseline and 6, 12. 18, and 24 months after randomization.
For evaluating adrenal cortical function, cortisol, aldosterone, and dehydroepiandrostenedione sulfate (DHEA-S) levels were measured before and 30, 60, and 90 minutes after intravenous administration of 250 ug synthetic corticotropin (Cortrosyn, Organon, West Orange. NJ): basal corticotropin and renin levels were also measured.
Gonadal function was evaluated by measuring basal levels of serum progesterone, prolactin, follicle-stimulating hormone (FSH). luteinizing hormone (LH), total and free testosterone.
and estradiol. In a subset of men, a semen analysis was obtained and serum testosterone level was measured 24 and 48 hours after intramuscular injection of HCG 2.500 IU. All blood was obtained between the hours of 8:00 and 10:00 AM and immediately centrifuged; serum was shipped on dry ice to a central laboratory where all samples were assayed. One semen sample was obtained at each time point from participants from Johns Hopkins University and the University of Michigan after a period of abstinence of 3 days. Significant illnesses during the previous 3 months were documented.
Men were recruited into the study over a l-year period, thus permitting serum samples to be collected through all seasons. Semen analyses were performed within 2 hours of obtaining the sample by a dedicated technician for each site (with a second one available for vacations, etc.) in the following manner. Density was determined manually using a counting chamber, and percent motility was reported after a manual observation of 200 sperm. Criteria for normal sperm morphology were determined manually by the presence of a sheath. head. and a single tail. A nigrosin-eosinophil stain was performed to determine the viability of the sperm; the degree of dye uptake correlates with the percent normal morphology.
Assays
All hormone measurements were performed by radioimmunoassay; all individual samples were assayed in the same assay. All steroid hormone levels (cortisol [sensitivity, 0. 
Statistical Analysis
Statistical analysis was performed using Statistical Analysis Systems (SAS Institute, Gary. NC) on a mainframe computer and CLINFO in The Johns Hopkins University School of Hygiene and Public Health. Data were analyzed using two approaches.
In the first, all subjects were grouped as a whole without distinction for treatment assignment.
In the second. patients were classified into DOBS, SARMA, AND SCHTEINGART the first year of the clinical trial; a subset of 10 patients continued for 24 months. There were no statistically significant differences in baseline age, gender distribution, or total serum cholesterol or LDL-C concentrations between the two groups at initiation of the study (Table 1) . At 24 months, LDL-C levels decreased by 42% + 3% in group I and 44% ? 1% in Group II (P < .OOl v baseline, NS between groups). Drug dosages were altered to maintain serum LDL-C concentrations between the 25th and 50th percentile for age and gender.ls Based on tablet counts at each visit, there was a 93% compliance rate in both groups.
two treatment groups (group I = pravastatin with or without other lipid-lowering agents, group II = other lipid-lowering agents without pravastatin). Data from the one premenopausal woman in the study was excluded in analyzing female gonadal function. Sample sizes were calculated to detect a difference in serum testosterone levels of at least 30% between groups at 12 months with a power of 0.8 and an cx of .05.
Effects on Adrenal Function
Data are presented as means ? standard error of the mean. The null hypothesis was rejected at a P value of less than .05. Statistical tests included paired or unpaired Student's t test and repeatedmeasures ANOVA. For those variables analyzed by the ANOVA model, we assessed the effect of treatment group, month of testing, and their interaction. Corticotropin-and HCG-stimulation tests were analyzed by evaluating the area under the response curve and the peak 6 (maximum serum level minus basal concentration) response. Men and women were analyzed separately for serum total and free testosterone, estradiol, progesterone, FSH, and LH determinations.
DHEA-S.
Mean basal serum DHEA-S levels did not change significantly in either group (Table 2 ). In contrast, the DHEA-S response (peak -basal levels) to Cortrosyn administration decreased in patients tested at 6 months (n = 46; paired Student's t
RESULTS

Baseline
(aged 52 k 1 years, women postmenopausal) participated in a prospective endocrine evaluation
Cortisol.
basal cortisol levels remained (Table 2) . Similarly, basal corticotropin levels did not change. The cortisol response to corticotropin months did not change ment, the mean concentration (Tables 3 and 4 ). Only one woman was premenopausal, and there were no statistically significant changes in her serum levels (data not shown). Among the men, 28 subjects (72%) showed a decrease in basal total testosterone levels at 12 months regardless of treatment assignment; however, these changes were not statistically significant. months was significantly higher (10.6 * 1.5 pg/dL) than that observed at baseline (8.3 2 0.7 ug/dL, P < .Ol). However, basal concentrations (8.8 2 1.4 ,ug/&., n = 10) re; turned to baseline by 18 months (Table 2) . Although a between-group comparison could not be performed at 18 months because of a small sample size, the aldosterone response to corticotropin administration did not change over the l&month period (Fig 2C) .
Eff&s on Gonadal Function
There were no statistically significant differences in mean basal levels of total or free testosterone, FSH, LH, estradial, or progesterone over a period of 24 months for either A subset of 10 men with a mean age (48 t 4 years) similar to that of the group as a whole received an HCG stimulation test and semen analysis; only data through 12 months are presented since the sample sizes were small at 18 and 24 months. Total (Fig 3A) and free testosterone ( Fig  3B) response (peak -basal levels) to the administration of HCG did not change with treatment during 24 months of follow-up evaluation. A decrease in mean semen volume and sperm count was observed at 6 months (P < .05) in all men regardless of treatment assignment; values returned toward baseline by 12 months. Mean sperm motility decreased in men from both groups at 6 and 12 months (P < .OS). No differences were noted in these variables between group I and group II (Fig 4) .
DISCUSSION
We sought to compare the long-term effects of decreasing LDL-C levels on steroid hormone metabolism using an HMG-CoA reductase inhibitor. In our patients studied over 2 years, basal cortisol and DHEA-S levels did not change with pravastatin use. The increase in basal aldosterone levels at 12 months (P < .05) was not specific for pravastatin, since it was observed in subjects regardless of treatment assignment. The secretory reserve of cortisol and aldosterone, as determined by a Cortrosyn stimulation test, was maintained throughout the study. However, the capacity-to stimulate DHEA-S secretion in response to corticotropin decreased in subjects from both groups regardless of treatment assignment. Thus this occurred even with cholestyramine, which does not affect de novo synthesis of cholesterol within the adrenal gland. This finding is difficult to interpret and is probably clinically insignifcant, since DHEA-S has such a long serum half-life.
In this study, men and postmenopausal women maintained basal sex hormone secretion throughout the 2 years. Possible detrimental effects on premenopausal women cannot be excluded from this investigation.
Obviously, it would be unlikely to detect changes in serum progesterone levels, since this hormone is secreted in such low concentrations in postmenopausal women. Semen analyses obtained in a subset of men showed reductions in sperm count, motility, and percent normal sperm over the course of 2 years in men in both groups. There were no dilferenccs noted between those men treated with pravastatin versus those treated with other lipid-lowering agents. Although patients were given strict instructions on how to obtain fresh samples, semen analyses can be difficult to interpret, especially since there is considerable variation for individual semen specimens from the same subject, Sexual function was not adequately investigated.
The lack of effect of pravastatin compared with resin on steroid hormone metabolism that we observed in this study DOW, SARMA, AND SCHTEINGART may be a function of the pravastatin dose or tissue specificis no evidence for this, perhaps at abnormally low levels of ity. It is unlikely that drug dosage would have an effect, serum lipids there may be harmful effects on steroid since subjects varied their drug dosages throughout the synthesis. The study subjects were at best brought into the study depending on their serum lipid ltvels. Although there normal range. Tissue specificity may account for the limited effect of pravastatin, since the drug induced less than a 14% inhibition of cholesterol synthesis in vivo in mouse adrenal and testis as compared with a 90% inhibition noted in the liver and ileum.' In male Wistar rats, pravastatin (CS-514) elicited a 7.6% and 7.8% inhibition of sterol synthesis in the testis and adrenal gland, respectively. 6 Similarly, pravastatin was unable to enter the intact lens of rats and was 100-fold less inhibitory of [14C]acetate incorporation into cholesterol in the lens compared with lovastatin or simvastatinz4
In summary, basal and Cortrosyn-stimulated cortisol and aldosterone secretion did not change during treatment with pravastatin. The secretory response of DHEA-S to corticotropin administration was impaired at 6 and 12 months; however, this effect was also noted in a control group receiving cholestyramine.
Testicular function, as evaluated by basal and HCG-stimulated testosterone levels, did not change. Since the changes recorded were observed in both the pravastatin-treated patients and in those treated with other lipid-lowering agents, it is possible that any impairment in steroid hormone secretion is a function of the decrease in lipid levels rather than a specific effect of HMG-CoA redactase inhibition.
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